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Toxoplasma gondii is an important opportunistic pathogen for immunocompromised patients and respon-
sible for toxoplasmic encephalitis, which is often lethal. Treatment for this infection is limited to a
restricted therapeutic arsenal. In this work we tested the combination of ﬂuconazole with the current
treatment for acute toxoplasmosis on the murine model in vivo. Different experimental groups were trea-
ted with combinations of sulfadiazine plus pyrimethamine with ﬂuconazole and pyrimethamine with
ﬂuconazole. Fluconazole is an important antifungal triazole used against others CNS related opportunistic
pathogens such as Cryptococcus neoformans and Candida spp. The combinations of ﬂuconazole plus sulfa-
diazine and pyrimethamine or ﬂuconazole plus pyrimethamine were remarkably effective against T. gon-
dii in vivo. The 10-day treatment with 10 mg/kg/day of ﬂuconazole combined with 40/1 mg/kg/day
sulfadiazine and pyrimethamine resulted in 93% survival of CF1 mice acutely infected with the highly vir-
ulent T. gondii RH strain, versus 36% of mice treated with just sulfadiazine and pyrimethamine. Combina-
tions of ﬂuconazole with lower doses of sulfadiazine and pyrimethamine or with just pyrimethamine
were also efﬁcient in reducing the mortality of mice compared with the treatment without ﬂuconazole.
The results obtained are promising for the treatment of human toxoplasmosis and point to the need to
extend these studies to other murine models.
 2012 Elsevier Inc. Open access under the Elsevier OA license.ltraestrutura Celular Hertha
FRJ, CCS, Bloco G, Av. Carlos
21941-902, Rio de Janeiro, RJ,
aro).
sevier OA license.1. Introduction
Toxoplasmosis is an important opportunistic disease in immu-
nocompromised patients and is caused by the protozoan Toxo-
plasma gondii (Luft and Remington, 1988; Singer et al., 2010). In
HIV patients, cerebral toxoplasmosis is the most frequent cause
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Vidal et al., 2005). The introduction of the highly active antiretro-
viral therapy (HAART) has reduced the incidence of toxoplasmic
encephalitis (TE) and other opportunistic diseases in AIDS patients;
however, TE is still responsible for extensive mortality and morbid-
ity in immunocompromised patients. The lack of or inadequate
HAART treatment and an ineffective program for HIV diagnosis in
some geographical areas are acclaimed to be the main factors for
TE incidence. Many HIV patients are hospitalized only when the
CNS is affected, and in many cases, both TE and HIV are co-diag-
nosed (Antinori et al., 2004; Kiderlen et al., 2011; Nobre et al.,
2003; Vidal et al., 2005). In addition, ocular toxoplasmosis is fre-
quently found in AIDS patients presenting TE, which is usually very
aggressive (Commodaro et al., 2009).
The treatment of toxoplasmosis consists in the combination of
pyrimethamine (PYR) and sulfadiazine (SDZ), or in cases of sulfa
intolerance, pyrimethamine is combined with clindamycin. The
co-administration of folinic acid is also included in order to mini-
mize the toxic effects of pyrimethamine in patients. However, both
managements are commonly linked to side effects in TE patients,
which can lead to the interruption of the full 4–6 week therapy
course and cause a relapse of the disease (Katlama et al., 1996).
The fungi Cryptococcus neoformans and Candida spp. are impor-
tant opportunistic pathogens in immunocompromised patients
(Nobre et al., 2003). C. neoformans is an important CNS related
opportunistic pathogen and the most frequent cause of HIV-associ-
ated meningitis. Amphotericin B plus ﬂucytosine is the choice ther-
apy for cryptococcosis, but administration of ﬂuconazole is also
used for the consolidation therapy or the maintenance of the treat-
ment in patients (Singer et al., 2010). For candidiasis treatment,
ﬂuconazole is the ﬁrst line therapy (Thompson et al., 2010). Fluco-
nazole is a ﬁrst-generation triazole drug, which was introduced in
the early 90s, and is known for its favorable pharmacokinetics and
wide therapeutic index (Lass-Flörl, 2011).
Although co-infections of T. gondii and C. neoformans or Candida
spp. are common in AIDS patients (Kiderlen et al., 2011; Luft and
Remington, 1988), the effect of the combination of sulfadiazine
and pyrimethamine with ﬂuconazole has never been investigated
for the treatment of toxoplasmosis. A previous study by our group
showed that ﬂuconazole treatment enhances the survival of mice
acutely infected with T. gondii (Martins-Duarte et al., 2010). Thus,
in this study we investigated the effect of the association of the
antifungal ﬂuconazole (FLZ) with sulfadiazine (SDZ) plus pyri-
methamine (PYR) or just FLZ with PYR, in the treatment of mice
acutely infected with T. gondii. The results obtained showed the
greater efﬁcacy of these combinations in comparison with the cur-
rent therapy (SDZ + PYR) to enhance mouse survival in T. gondii
infections.2. Experimental methodology
2.1. Parasites
Tachyzoites of the RH strain were used for the in vitro and
in vivo tests and were obtained from the peritoneal cavities of mice
2 days after infection.2.2. Mice
Four to six week-old female CF1 mice weighing 18–22 g at the
beginning of the experiment were used for the in vivo experiments.
Drinking water and food were given ad libitum. The experimental
protocols for animal use in this study were approved by the Insti-
tutional Ethics Committee for Animal Use (approval ID: CEUA/CCS/
UFRJ/IBCCF 100).2.3. Drugs
As the in vitro and in vivo sets of experiments had a long gap
(18 months) between them, two different purchases of ﬂuconazole
were made. For in vivo tests, 150 mg capsules of FLZ were pur-
chased from EMS Genéricos lot # 065313 (EMS, São Paulo, Brazil).
For in vitro assays 150 mg capsules of FLZ were purchased from
Zydus lot # MG6351 (Cadila Healthcare Ltd., Ahmedabad, India).
For obtaining the quantity of ﬂuconazole required for the in vivo
tests or stock solution preparation for the in vitro experiments,
all the content of the capsule was weighted and a correction factor
was calculated considering the excipient content (for example: fac-
tor = 400 mg (total content of capsule)/150 mg of ﬂuconaz-
ole = 2.67; i.e. 2.67 mg of capsule content was equivalent to 1 mg
of ﬂuconazole). Sulfadiazine and pyrimethamine were purchased
from Sigma (Sigma–Aldrich, St. Louis, USA). For in vivo tests the
drugs were diluted in poly-ethylene glycol (PEG) mol. wt. 200 (Sig-
ma–Aldrich, St. Louis, USA), and for the in vitro experiments, the
drugs were diluted in DMSO (Merck KGaA, Darmstadt, Germany).
2.4. In vitro antiproliferative assay
Approximately 1.5–2.0  106 LLC-MK2 cells (kidney, Rhesus
monkey, Macaca mulata – ATCC CCL7, Rockville, MD, USA) placed
in a 24-well tissue culture plate were infected at the ratio of
10:1 parasite/host cell with freshly obtained RH strain parasites
resuspended in RPMI medium. The cells and the tachyzoites were
allowed to interact for 1 h and then they were washed twice with
RPMI to remove unattached parasites. Treatment started 6 h after
infection. Different concentrations of FLZ (0.05, 0.1, 0.5, 1.0 and
3.0 lM) were added to the dose response curves of SDZ/PYR
(0.1 lM/0.4 nM to 100 lM/0.4 lM) and to PYR (4 nM–4 lM). Dose
response curves of FLZ plus SDZ/PYR and FLZ plus PYR were also
made. After 24 h of treatment, the cells were ﬁxed with Bouin,
stained with Panotico kit solutions 2 and 3 (Laborclin Ltda, Paraná,
Brazil) and observed under a light microscope. The antiprolifera-
tive effect was evaluated after examining at least 1200 cells in
two different coverslips for each concentration. The parasite prolif-
eration index was determined by multiplying the percentage of in-
fected cells by the total number of intracellular parasites and
divided by the total number of cells. The 50% inhibitory concentra-
tion (IC50) was calculated using a sigmoidal dose response curve in
Sigma Plot 8.0 software (Systat Software Inc., Chicago, IL, USA).
2.5. Drug interaction in vitro
The fractional inhibitory concentration (FICI) values were calcu-
lated according to the Loewe additive model, deﬁned by the equa-
tion a/A + b/B = 1, where A and B are the IC50 of individual drugs
and a and b are the IC50 of the drugs in combination (Tallarida,
2006). The combination effect was analyzed according to FICI val-
ues: 60.5, synergism; >0.5–4, no interaction; and >4, antagonism
(Odds, 2003).
2.6. Cell toxicity experiments
The effect of the combinations of FLZ and SDZ/PYR or PYR on
LLC-MK2 cells was evaluated by the MTS assay. For that, 2  105
cells were placed in a 96-well tissue plate and treated for 24 h with
the same combined doses of FLZ and SDZ/PYR or PYR utilized for
the in vitro test against T. gondii. At the end of incubation time, cells
were washed with PBS, each well was ﬁlled with 100 lL of 10 mM
Glucose in PBS and 20 lL of MTS reagent (Promega, Madison, WI,
USA) was added. The absorbance was read at 490 nm after 3 h of
incubation and cytotoxicity was calculated as the percentage of
viable cells versus untreated cells (control).
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For the in vivo study, mice were infected intraperitoneally (i.p.)
with tachyzoites of the RH strain of T. gondii. Treatment was initi-
ated 24 h post infection and groups of three or four mice were
housed per cage and arbitrarily assigned to administration with
FLZ plus SDZ/PYR or FLZ plus PYR or left untreated as the control
group. PEG (diluent) was administrated to the untreated mice.
The treatment lasted for 10 days and the drugs were administrated
orally by gavage once a day. The mice and the mortality rates were
monitored for a period of 90 days. The survival curves and the
median survival (day at which fractional survival equals 50%) were
calculated using the product limit method of Kaplan and Meier,
and the comparison of the survival curves was carried out using
the log-rank (Mantel–Cox) test in Graphpad Prism 5.0 (GraphPad
Software Inc.). P 6 0.05 was considered statistically signiﬁcant.3. Results
3.1. Effect of the in vitro combination of FLZ with SDZ/PYR or FLZ with
PYR
The in vitro interactions of FLZ plus SDZ/PYR and FLZ plus PYR
were evaluated by the addition of ﬁxed concentrations of FLZ
(0.05, 0.1, 0.5, 1.0 and 3.0 lM) to the dose effect curves of SDZ/
PYR or to the PYR curves (Table 1). FLZ, SDZ/PYR and PYR single
curves were also performed in parallel to drug combined experi-
ments and the IC50 and FICI values were calculated for each exper-
iment and are the mean of three independent experiments. The FLZ
IC50 obtained were 8.4 ± 1.2 and 8.7 ± 0.8 for combinations with
SDZ/PYR and PYR, respectively. The majority of the different FLZ
treatments with either SDZ/PYR or PYR did not exert a synergistic
effect in vitro. The addition of 0.1 lM FLZ to SDZ/PYR was the only
combination which resulted in a synergistic effect, as it lowered
the SDZ/PYR IC50 by more than two-fold (15.0–7.1 lM) producing
a FICI of 0.5. However, none of the other combinations evaluated
caused a signiﬁcant reduction of the SDZ/PYR IC50 or PYR IC50
and resulted in indexes close to 1.
Toxicity studies of the different combinations on LLC-MK2 pro-
liferation after 24 h of treatment showed that combined concentra-
tions of FLZ with SDZ/PYR or PYR did not affect signiﬁcantly host
cell proliferation (Table 2).3.2. Combination of FLZ plus SDZ/PYR in vivo
In a preliminary test with only one experimental group (3 mice
per experiment), the effect of different doses of FLZ alone against
mice infected with 103 tachyzoites of RH strain was evaluated.
The treatment with doses of 20, 40 or 80 mg/kg/day of FLZ aloneTable 1
IC50 and FICI obtained for the in vitro combination of different concentrations of FLZ
plus SDZ/PYR and FLZ plus PYR against T. gondii.
FLZa (lM) SDZ/PYR PYR
IC50 (lM/nM) FICIb IC50 (lM) FICIb
0.0 15.0 ± 2.8/60.0 ± 11.2 – 0.23 ± 0.10 –
0.05 14.4 ± 2.0/57.6 ± 8.0 1.0 0.19 ± 0.06 0.8
0.1 7.1 ± 0.5/28.4 ± 2.0 0.5 0.23 ± 0.08 1.0
0.5 12.3 ± 2.1/49.2 ± 8.4 0.9 0.34 ± 0.13 1.5
1.0 9.2 ± 1,9/36.8 ± 7.6 0.7 0.14 ± 0.07 0.7
3.0 13.3 ± 3.6/53.2 ± 14.4 1.2 0.19 ± 0.05 1.2
Results are the mean ± standard deviation of three different experiments.
a FLZ IC50 were 8.4 ± 1.2 and 8.7 ± 0.8 for combinations with SDZ/PYR and PYR,
respectively.
b FICI values of 60.5; >0.5–4; and >4, indicate synergism, no interaction or
antagonism, respectively.did not prolong mouse survival compared with untreated, and ani-
mals died after 7–9 days (data not shown).
The combination of FLZ plus SDZ/PYR achieved signiﬁcant re-
sults in survival. Protection from death increased signiﬁcantly for
mice treated with 10 mg/kg/day of FLZ combined to 40/1 mg/kg/
day of SDZ/PYR (P = 0.0015). At the end of 90 days 93% of mice trea-
ted with this combination were alive versus 36% (median survival
of 31 days) of mice treated only with 40/1 mg of SDZ/PYR (Fig. 1A).
In a separate experiment, the treatment with 5 or 20 mg of FLZ
combined to 40/1 mg SDZ/PYR also increased mouse survival com-
pared to treatment with SDZ/PYR alone (Fig. 1B). At the end of
90 days, 73% and 91% of mice treated, with combinations of 5 mg
and 20 mg of FLZ, respectively, continued alive, versus 33% (med-
ian survival of 43 days) of mice treated with SDZ/PYR alone. How-
ever, only the combination with 20 mg of FLZ was statistically
signiﬁcant (P = 0.008).
Mice treated with a lower dose of SDZ/PYR (20/0.5 mg) and dif-
ferent doses of FLZ also increased mouse survival compared to the
treatment with only SDZ/PYR (Fig. 2). The combination with 20 mg
of FLZ achieved the best result in mouse survival compared to SDZ/
PYR alone and the combinations of 10 or 40 mg of FLZ, protecting
25% of mice from death with a median survival of 25 days
(P < 0.05). Mice only treated with SDZ/PYR died after 43 days and
had a median survival of 15 days. Combinations of 10 or 40 mg
of FLZ did not protect mice from death, and resulted in a median
survival of 21 and 22 days, respectively. Although these combina-
tions had enhanced mouse survival compared to treatment with
only SDZ/PYR, the differences between these groups were not sta-
tistically signiﬁcant (P > 0.05).3.3. Combination of FLZ and PYR in vivo
PYR is considered the drug more active to treat T. gondii infec-
tions, thus a combination of just PYR with FLZ was also evaluated.
The effect of different doses (20, 40 or 80 mg/kg/day) of FLZ com-
bined with 1, 5 or 10 mg/kg/day of just PYR was evaluated. The
combination with 1 mg of PYR, which was the highest dose used
in the tests with SDZ/PYR, did not result in any improvement in
mouse survival compared to the treatment with PYR alone or to
untreated mice (data not shown). On the other hand, mice treated
with combinations of FLZ plus 5 or 10 mg of PYR prolonged mouse
survival (Fig. 3A and B). The treatment with all doses of FLZ com-
bined to 5 mg of PYR resulted in a signiﬁcant enhancement in
mouse survival compared to PYR monotherapy (Fig. 3A). Mice trea-
ted with only 5 mg of PYR had a median of survival of 9 days, a
slight difference compared to the median survival of 8 days of un-
treated ones. However, mice treated with combinations of 20 mg,
40 mg and 80 mg of FLZ and 5 mg of PYR had a median of survival
of 23 days, 12 days and 16.5 days, respectively (P < 0.05 versus PYR
5 mg). The combination with 80 mg of FLZ plus 5 mg of PYR pro-
tected only 1 mouse (8.3%) from death.
The combinations of FLZ plus 10 mg of PYR (Fig. 3B) also signif-
icantly enhanced mouse survival, and results were better than the
combination with 5 mg of PYR. The different dose of FLZ combined
to 10 mg of PYR had a dose dependent effect on mouse survival, as
20 mg, 40 mg and 80 mg of FLZ protected 42%, 54% and 64% of mice
from death, respectively (P < 0.05 versus PYR 10 mg). Mice treated
only with 10 mg of PYR survived up to 32 days and had a median
survival of 21 days (P < 0.05).4. Discussion
The evaluation of drugs available on themarket is a good strategy
for the discovery of new potential therapies, as they have been pre-
viously approved for human use. FLZ is a drug that is well-tolerated
Table 2
Percentage of host cell proliferation after 24 h of treatment with different combined concentrations of FLZ and SDZ/PYR or PYR.
FLZ (lM) SDZ/PYR (lM) PYR (lM)
0.1/0.0004 1.0/0.004 10/0.04 100/0.4 0.004 0.04 0.4 4.0
0.0 99 ± 1 94 ± 10 97 ± 5 99 ± 2 96 ± 8 100 97 ± 5 97 ± 5
0.05 100 95 ± 8 96 ± 4 91 ± 11 93 ± 7 96 ± 7 95 ± 2 88 ± 12
0.1 97 ± 6 99 ± 1 99 ± 2 93 ± 6 90 ± 9 90 ± 2 96 ± 5 94 ± 11
0.5 90 ± 15 95 ± 8 95 ± 7 88 ± 14 92 ± 8 95 ± 5 89 ± 5 86 ± 5
1.0 97 ± 5 99 ± 2 95 ± 2 97 ± 4 94 ± 10 92 ± 3 96 ± 8 93 ± 11
3.0 95 ± 9 98 ± 3 97 ± 5 91 ± 10 93 ± 8 92 ± 6 83 ± 6 89 ± 7
Results are the mean ± standard deviation of three different experiments.
Fig. 1. Effect of a 10 day treatment with a combination of 10 mg/kg/day of FLZ + 40/
1.0 mg/kg/day of SDZ /PYR (A) or 5 or 20 mg/kg/day of FLZ + 40/1.0 mg/kg/day of
SDZ/PYR (B) on the survival of Swiss mice acutely infected with 103 tachyzoites of T.
gondii RH strain. The results were evaluated by Kaplan–Meier product limit method.
P < 0.05 for the combination of 10 and 20 mg of FLZ versus SDZ/PYR; P > 0.05 for the
combination of 5 mg of FLZ versus SDZ/PYR. (A) Untreated (n = 14; four groups);
SDZ 40/PYR 1 (n = 14; four groups); SDZ 40/PYR 1 + FLZ 10 (n = 14; four groups). (B)
Untreated (n = 11, three groups); SDZ 40/PYR 1 (n = 12; three groups); SDZ 40/PYR
1 + FLZ 5 (n = 11; three groups); SDZ 40/PYR 1 + FLZ 20 (n = 11; three groups).
Fig. 2. Effect of a 10 day treatment with a combination of 10 or 20 or 40 mg/kg/day
FLZ + 20/0.5 mg/kg/day SDZ /PYR on the survival of Swiss mice acutely infected
with 103 tachyzoites of T. gondii RH strain. The results were evaluated by Kaplan–
Meier product limit method. P < 0.05 for the combination of 20 mg FLZ versus SDZ/
PYR; P > 0.05 for the combinations of 10 or 40 mg FLZ versus SDZ/PYR. Untreated
(n = 12; three groups); SDZ 20/PYR 0.5 (n = 12; three groups); SDZ 20/PYR0.5 + FLZ
10 (n = 4; one group); SDZ 20/PYR0.5 + FLZ 20 (n = 12; three groups); SDZ 20/
PYR0.5 + FLZ 40 (n = 12; three groups).
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monly administered for the treatment of fungal infections in HIV
patients. The fungistatic effects of azoles involve the inhibition of
ergosterol synthesis at the level of the C-14 a-lanosterol demethyl-
ase (Koltin and Hitchcock, 1997), and although this pathway is ab-
sent in Apicomplexa parasites, previous studies have shown that
azoles displayed a strong effect against T. gondii and Plasmodium fal-
ciparum (Martins-Duarte et al., 2008, 2010; Penna-Coutinho et al.,
2011). The anti-Plasmodium effect of itraconazole and posaconazole
was suggested to be due to a competition of theNADH for the lactate
dehydrogenase (Penna-Coutinho et al., 2011). The low in vitro IC50
obtained for FLZ and itraconazole (Martins-Duarte et al., 2008,
2010), as well as, the in vivo effect of FLZ against T. gondii indicate
the presence of a selective molecular target in T. gondii.
The use of a combined therapy is recognized as themost effective
treatment for TE (Fung and Kirschenbaum, 1996; Katlama et al.,
1996). Human treatment with a PYR monotherapy is not recom-
mended, as patients in maintenance therapy with PYR alone were
more susceptible to relapses of the disease (Foppa et al., 1991). Be-
sides, the combinedadministrationof drugsmight lead to adecrease
in drug dosages, while maintaining the therapeutic efﬁcacy and
reducing toxicity related to the treatment. In addition, it may reach
multiple targets or multiple diseases simultaneously (Chou, 2006).
Thus the study of new drug combinations is a promising strategy
for discovering therapies for the treatment of toxoplasmosis.
For the combined tests with SDZ/PYR we decided to use a dose
relation similar to the clinical management for the treatment of
human patients presenting TE: 50–100 mg/day of PYR and 4–8 g/
day of SDZ (Fung and Kirschenbaum, 1996). Although the relation
of the SDZ/PYR dose can vary from 40–160/1, we chose a relation
dose of 40/1.
The results obtained indicate that both combinations of FLZ plus
SDZ/PYR and FLZ plus PYR are highly effective against T. gondii
in vivo. The anti-T. gondii activity in vivo of FLZ against mice in-
fected with the Me49 strain was previously reported by our group
(Martins-Duarte et al., 2010), and the lack of effect against mice
infected with the RH strain is possibly due to the highly virulent
nature of this strain for mice. However, when FLZ in combination
with SDZ/PYR or with PYR was administrated against mice infected
with the RH strain, a signiﬁcant difference in survival and in pro-
tection was obtained against relapses and death from the disease,
compared with the administration of SDZ/PYR or PYR without FLZ.
The combination of 10 or 20 mg of FLZ with 40/1 mg/kg/day of
SDZ/PYR had similar results in mouse survival and the combination
of 20 mg of FLZ to a reduced dose of SDZ/PYR (20/0.5 mg) also im-
proved mouse survival signiﬁcantly compared to treatment with
only SDZ/PYR. This observation is very interesting, since a reduc-
tion in SDZ/PYR doses will also diminish the side effects. However,
the decrease in mouse survival when 40 mg of FLZ was used might
suggest an antagonism effect with high doses of FLZ and SDZ/PYR.
Differently to the treatment with SDZ/PYR plus FLZ, the combina-
tion of FLZ with PYR showed a dose dependent effect; the increase
of the FLZ dose enhanced mouse protection from death.
Fig. 3. Effect of a 10 day treatment with a combination of PYR 5.0 mg/kg/day + 20
or 40 or 80 mg/kg/day FLZ (A) and PYR 10 mg/kg/day + 20 or 40 or 80 mg/kg/day
FLZ (B) on the survival of Swiss mice acutely infected with 103 tachyzoites of T.
gondii RH strain. The results were evaluated by Kaplan–Meier product limit method
P < 0.05 for all combinations versus PYR. (A) Untreated (n = 12; three groups); PYR 5
(n = 12; three groups); PYR 5 + FLZ 20 (n = 7; two groups); PYR 5 + FLZ 40 (n = 12;
three groups); PYR 5 + FLZ 80 (n = 12). (B) Untreated (n = 14; four groups); PYR 10
(n = 14; four groups); PYR 10 + FLZ 20 (n = 7; two groups); PYR 10 + FLZ 40 (n = 11;
three groups); PYR 10 + FLZ 80 (n = 14; four groups).
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FLZ is lower than the highest dose (800 mg/day, 12 mg/kg)
administered to treat patients with fungus infections (Hope et al.,
2008), and currently the administration of doses up to 1200 mg/
day (18 mg/kg) have been considered for the treatment of crypto-
coccal meningitis (Nussbaum et al., 2010). The treatment with
doses of FLZ up to 1600 mg/day (24 mg/kg) is well tolerated,
and although the treatment with 2000 mg/day (30 mg/kg) led to
central nervous system side effects in some patients, this dose pos-
sess a safe proﬁle (Anaissie et al., 1995; Voss and De Pauw, 1999).
The in vivo effect suggests a synergistic interaction of FLZ plus SDZ/
PYR and FLZ plus PYR, but when the combination effect was eval-
uated in vitro the drugs only had an additive effect. The in vitro
combination of clindamycin and PYR did not result in synergic
interaction (Harris et al., 1988), but the administration of clinda-
mycin and PYR is effective for the treatment of TE patients. Thus,
the lack of in vitro synergism does not preclude in vivo efﬁcacy.
However, a pharmacokinetic interaction cannot be excluded as
FLZ is a known inhibitor of cytochrome P450 (CYP) oxidative
metabolism. FLZ is a strong non-competitive inhibitor of CYP iso-
form 2C9, and can affect the biotransformation of other drugs
(Gubbins and Amsden, 2005). CYP2C9 was shown to metabolize
SDZ to its hydroxylamine intermediate in experiments utilizing
human liver microsomes in vitro (Winter and Unadkat, 2005), thus
the enhancement of the SDZ/PYR effect when combined to FLZ may
be due to an increase of SDZ blood concentrations caused by the
reduction on SDZ metabolism by FLZ. There is little information
about the metabolism of PYR and although it is believed to be he-
patic (Cavallito et al., 1978), the PYR metabolism by CYP oxidative
enzymes was not detectable in vitro (Li et al., 2003).
In conclusion, the potential combinations of FLZ and SDZ/PYR or
FLZ and PYR point to the need to extend these studies in other
murine models aiming for a new treatment of human toxoplasmo-sis. The administration of FLZ should be considered as a possibility
to improve SDZ/PYR efﬁcacy for the treatment of toxoplasmosis,
leading to faster recovery and less relapses of the disease. Also such
combinations are an opportunity, to decrease SDZ/PYR doses and
their related side effects. The combination of FLZ and PYR may be
also considered as an option to substitute the administration of
SDZ/PYR in cases of intolerance to SDZ.Acknowledgments
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